NO320715B1 - Nye peptider avledet av humant varmesjokkprotein 60, farmasoytiske preparater omfattende slike og anvendelse av de nye peptider for fremstilling av farmasoytiske preparater for behandling og forebyggelse av insulinavhengig diabetes mellitus, samt fremgangsmate og sett for diagnostisering av IDDM. - Google Patents

Nye peptider avledet av humant varmesjokkprotein 60, farmasoytiske preparater omfattende slike og anvendelse av de nye peptider for fremstilling av farmasoytiske preparater for behandling og forebyggelse av insulinavhengig diabetes mellitus, samt fremgangsmate og sett for diagnostisering av IDDM. Download PDF

Info

Publication number: NO320715B1
Authority: NO; Norway
Prior art keywords: hsp60; peptide; iddm; cell; cells
Prior art date: 1995-06-30

Application number

NO19976094A

Other languages

English (en)

Norwegian (no)

Other versions

NO976094D0 (no

NO976094L (no

Inventor

Dana Elias

Irun R Cohen

Rivka Abulafia

Jana Bockova

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-30

Filing date

1997-12-29

Publication date

2006-01-23

1997-12-29 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

1997-12-29 Publication of NO976094D0 publication Critical patent/NO976094D0/no

1998-02-02 Publication of NO976094L publication Critical patent/NO976094L/no

2006-01-23 Publication of NO320715B1 publication Critical patent/NO320715B1/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 135
206010067584 Type 1 diabetes mellitus Diseases 0.000 title claims description 60
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 title claims description 55
238000000034 method Methods 0.000 title claims description 27
238000011282 treatment Methods 0.000 title claims description 26
239000008194 pharmaceutical composition Substances 0.000 title claims description 9
238000002360 preparation method Methods 0.000 title claims description 9
238000003745 diagnosis Methods 0.000 title claims description 6
230000002265 prevention Effects 0.000 title claims description 3
102000004196 processed proteins & peptides Human genes 0.000 title description 59
101000883686 Homo sapiens 60 kDa heat shock protein, mitochondrial Proteins 0.000 title description 4
102000006303 Chaperonin 60 Human genes 0.000 claims description 70
108010058432 Chaperonin 60 Proteins 0.000 claims description 70
210000001744 T-lymphocyte Anatomy 0.000 claims description 60
239000000427 antigen Substances 0.000 claims description 46
102000036639 antigens Human genes 0.000 claims description 44
108091007433 antigens Proteins 0.000 claims description 44
210000004369 blood Anatomy 0.000 claims description 27
239000008280 blood Substances 0.000 claims description 27
238000012360 testing method Methods 0.000 claims description 20
210000004027 cell Anatomy 0.000 claims description 16
230000004044 response Effects 0.000 claims description 12
239000002773 nucleotide Substances 0.000 claims description 9
125000003729 nucleotide group Chemical group 0.000 claims description 9
238000010348 incorporation Methods 0.000 claims description 7
210000005087 mononuclear cell Anatomy 0.000 claims description 7
210000002700 urine Anatomy 0.000 claims description 7
210000004698 lymphocyte Anatomy 0.000 claims description 6
230000002062 proliferating effect Effects 0.000 claims description 6
108090000695 Cytokines Proteins 0.000 claims description 5
102000004127 Cytokines Human genes 0.000 claims description 5
230000006052 T cell proliferation Effects 0.000 claims description 5
238000011534 incubation Methods 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
108090000978 Interleukin-4 Proteins 0.000 claims description 4
238000010998 test method Methods 0.000 claims description 4
238000002965 ELISA Methods 0.000 claims description 3
102000004190 Enzymes Human genes 0.000 claims description 3
108090000790 Enzymes Proteins 0.000 claims description 3
125000000539 amino acid group Chemical group 0.000 claims description 3
230000004071 biological effect Effects 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
102000003814 Interleukin-10 Human genes 0.000 claims description 2
108090000174 Interleukin-10 Proteins 0.000 claims description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
238000004113 cell culture Methods 0.000 claims description 2
238000000338 in vitro Methods 0.000 claims description 2
238000003127 radioimmunoassay Methods 0.000 claims description 2
239000007790 solid phase Substances 0.000 claims description 2
102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
238000012258 culturing Methods 0.000 claims 1
241000699670 Mus sp. Species 0.000 description 72
241000699666 Mus <mouse, genus> Species 0.000 description 37
206010012601 diabetes mellitus Diseases 0.000 description 32
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 28
230000009696 proliferative response Effects 0.000 description 17
102100024067 Inhibitor of growth protein 2 Human genes 0.000 description 16
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
239000008103 glucose Substances 0.000 description 12
230000002269 spontaneous effect Effects 0.000 description 11
230000001363 autoimmune Effects 0.000 description 10
230000002163 immunogen Effects 0.000 description 10
239000002953 phosphate buffered saline Substances 0.000 description 10
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 9
238000011161 development Methods 0.000 description 9
230000008569 process Effects 0.000 description 9
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
230000000638 stimulation Effects 0.000 description 8
241000611421 Elia Species 0.000 description 7
230000005867 T cell response Effects 0.000 description 7
210000003719 b-lymphocyte Anatomy 0.000 description 7
239000002609 medium Substances 0.000 description 7
239000000203 mixture Substances 0.000 description 7
229940104230 thymidine Drugs 0.000 description 7
238000004458 analytical method Methods 0.000 description 6
238000003556 assay Methods 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
230000000694 effects Effects 0.000 description 5
230000006698 induction Effects 0.000 description 5
230000035755 proliferation Effects 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
102100036948 DNA polymerase epsilon subunit 4 Human genes 0.000 description 4
206010018429 Glucose tolerance impaired Diseases 0.000 description 4
102000004877 Insulin Human genes 0.000 description 4
108090001061 Insulin Proteins 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 4
201000001421 hyperglycemia Diseases 0.000 description 4
229940125396 insulin Drugs 0.000 description 4
210000005259 peripheral blood Anatomy 0.000 description 4
239000011886 peripheral blood Substances 0.000 description 4
210000000952 spleen Anatomy 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
102000002812 Heat-Shock Proteins Human genes 0.000 description 3
108010004889 Heat-Shock Proteins Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
230000002788 anti-peptide Effects 0.000 description 3
230000005784 autoimmunity Effects 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
102000046432 human HSPD1 Human genes 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
210000001165 lymph node Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
101100327692 Caenorhabditis elegans hsp-60 gene Proteins 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
206010015943 Eye inflammation Diseases 0.000 description 2
108091022930 Glutamate decarboxylase Proteins 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
210000000548 hind-foot Anatomy 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
206010022000 influenza Diseases 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
239000008188 pellet Substances 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
229960001052 streptozocin Drugs 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
235000011330 Armoracia rusticana Nutrition 0.000 description 1
240000003291 Armoracia rusticana Species 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
238000000729 Fisher's exact test Methods 0.000 description 1
102000002464 Galactosidases Human genes 0.000 description 1
108010093031 Galactosidases Proteins 0.000 description 1
102000008214 Glutamate decarboxylase Human genes 0.000 description 1
101150023414 HSP60 gene Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
102000043131 MHC class II family Human genes 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
101000919317 Mus musculus Adapter molecule crk Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
NINIDFKCEFEMDL-AKLPVKDBSA-N Sulfur-35 Chemical compound [35S] NINIDFKCEFEMDL-AKLPVKDBSA-N 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000006472 autoimmune response Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
239000002619 cytotoxin Substances 0.000 description 1
230000001904 diabetogenic effect Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000013399 early diagnosis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
239000012530 fluid Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000014101 glucose homeostasis Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical group [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 description 1
229940044173 iodine-125 Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
235000020925 non fasting Nutrition 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000563 toxic property Toxicity 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
239000004474 valine Substances 0.000 description 1
231100000747 viability assay Toxicity 0.000 description 1
238000003026 viability measurement method Methods 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/80—Fluorescent dyes, e.g. rhodamine
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/804—Radioisotope, e.g. radioimmunoassay
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Diabetes (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Endocrinology (AREA)
Hematology (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO19976094A 1995-06-30 1997-12-29 Nye peptider avledet av humant varmesjokkprotein 60, farmasoytiske preparater omfattende slike og anvendelse av de nye peptider for fremstilling av farmasoytiske preparater for behandling og forebyggelse av insulinavhengig diabetes mellitus, samt fremgangsmate og sett for diagnostisering av IDDM. NO320715B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IL11440795A IL114407A0 (en)	1995-06-30	1995-06-30	Novel peptides and pharmaceutical compositions comprising them
PCT/US1996/011375 WO1997001959A1 (en)	1995-06-30	1996-07-01	Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits

Publications (3)

Publication Number	Publication Date
NO976094D0 NO976094D0 (no)	1997-12-29
NO976094L NO976094L (no)	1998-02-02
NO320715B1 true NO320715B1 (no)	2006-01-23

Family

ID=11067704

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19976094A NO320715B1 (no)	1995-06-30	1997-12-29	Nye peptider avledet av humant varmesjokkprotein 60, farmasoytiske preparater omfattende slike og anvendelse av de nye peptider for fremstilling av farmasoytiske preparater for behandling og forebyggelse av insulinavhengig diabetes mellitus, samt fremgangsmate og sett for diagnostisering av IDDM.

Country Status (19)

Country	Link
US (1)	US6682897B1 (de)
EP (1)	EP0845943B1 (de)
KR (1)	KR100454554B1 (de)
CN (1)	CN1102598C (de)
AR (1)	AR003446A1 (de)
AT (1)	ATE290315T1 (de)
AU (1)	AU710882B2 (de)
CA (1)	CA2225675C (de)
CZ (1)	CZ295110B6 (de)
DE (1)	DE69634438T2 (de)
DK (1)	DK0845943T3 (de)
ES (1)	ES2239770T3 (de)
HR (1)	HRP960307A2 (de)
HU (1)	HUP9901688A3 (de)
IL (2)	IL114407A0 (de)
NO (1)	NO320715B1 (de)
UY (1)	UY24270A1 (de)
WO (1)	WO1997001959A1 (de)
ZA (1)	ZA965565B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6488933B2 (en)	1995-07-05	2002-12-03	Yeda Research And Development Co. Ltd.	Preparations for the treatment of T cell mediated diseases
ATE249046T1 (de) *	1996-05-14	2003-09-15	Winnacker Ernst Ludwig Prof	Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können
US5993803A (en) *	1996-08-30	1999-11-30	Yeda Research And Development Co., Ltd.	Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
JP2004501061A (ja) *	1999-12-15	2004-01-15	ペプトル・リミテツド	熱ショックタンパク質６０のフラグメントおよびアンタゴニスト
EP1335741A4 (de) *	2000-08-25	2005-10-26	Yeda Res & Dev	METHODE ZUR PRÄVENTION VON AUTOIMMUNKRANKHEITEN MIT CpG-ENTHALTENDEN POLYNUCLEOTIDEN(04.03.02)
WO2003063759A2 (en)	2002-01-31	2003-08-07	Peptor Ltd.	Hsp peptides and analogs for modulation of immune responses via antigen presenting cells
WO2003070761A1 (en) *	2002-02-19	2003-08-28	Yeda Research And Development Co. Ltd.	Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation
AU2003230181A1 (en)	2002-05-21	2003-12-02	Yeda Research And Development Co. Ltd.	Dna vaccines encoding heat shock proteins
WO2004098489A2 (en) *	2003-05-12	2004-11-18	Peptor Ltd.	Compositions and methods for modulation of specific epitopes of hsp60
WO2005048914A2 (en) *	2003-11-24	2005-06-02	Yeda Research & Development Co. Ltd.	Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
EP1718158B1 (de)	2004-01-28	2014-07-02	Andromeda Bio Tech Ltd.	Hsp-behandlung in verbindung mit einer antigenitätsarmen diät
EP1835933A4 (de) *	2005-01-04	2015-01-07	Yeda Res & Dev	Hsp60, hsp60-peptide und t-zellen-impfstoffe zur immunmodulation
CU23701A1 (es) *	2008-12-29	2011-09-21	Ct Ingenieria Genetica Biotech	Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i
US9102942B2 (en)	2010-02-04	2015-08-11	EWHA University—Industry Collaboration Foundation	Pharmaceutical composition for inhibiting abnormal proliferation of cells
ITCO20120007A1 (it)	2012-02-21	2013-08-22	Nuovo Pignone Srl	Dispositivo di filtraggio dell'aria in ingresso per un impianto
WO2013128453A1 (en)	2012-03-01	2013-09-06	Yeda Research And Development Co. Ltd.	Regeneration of islet beta cells by hsp60 derived peptides
IN2014MN01887A (de)	2012-03-01	2015-07-10	Yeda Res & Dev
US10864253B2 (en) *	2016-04-29	2020-12-15	Araim Pharmaceuticals, Inc.	Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage
CN111035755B (zh) *	2020-01-08	2023-04-14	中国医学科学院医学生物学研究所	一种1型糖尿病疫苗及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5242823A (en) *	1986-03-07	1993-09-07	International Genetic Engineering, Inc.	Cloning of the 38kd Mycoplasma hyorhinis regression-associated antigen
US4976958A (en) *	1987-02-26	1990-12-11	Scripps Clinic And Research Foundation	Mycobacterial recombinants and peptides
US5114844A (en) *	1989-03-14	1992-05-19	Yeda Research And Development Co., Ltd.	Diagnosis and treatment of insulin dependent diabetes mellitus

1995
- 1995-06-30 IL IL11440795A patent/IL114407A0/xx unknown
1996
- 1996-06-28 UY UY24270A patent/UY24270A1/es unknown
- 1996-07-01 HU HU9901688A patent/HUP9901688A3/hu not_active Application Discontinuation
- 1996-07-01 AU AU64845/96A patent/AU710882B2/en not_active Expired
- 1996-07-01 CZ CZ19974117A patent/CZ295110B6/cs not_active IP Right Cessation
- 1996-07-01 WO PCT/US1996/011375 patent/WO1997001959A1/en not_active Ceased
- 1996-07-01 IL IL12275796A patent/IL122757A/en not_active IP Right Cessation
- 1996-07-01 HR HR114407A patent/HRP960307A2/hr not_active Application Discontinuation
- 1996-07-01 ES ES96924372T patent/ES2239770T3/es not_active Expired - Lifetime
- 1996-07-01 AR ARP960103410A patent/AR003446A1/es not_active Application Discontinuation
- 1996-07-01 DK DK96924372T patent/DK0845943T3/da active
- 1996-07-01 AT AT96924372T patent/ATE290315T1/de active
- 1996-07-01 DE DE69634438T patent/DE69634438T2/de not_active Expired - Lifetime
- 1996-07-01 ZA ZA9605565A patent/ZA965565B/xx unknown
- 1996-07-01 CN CN96196403A patent/CN1102598C/zh not_active Expired - Lifetime
- 1996-07-01 KR KR1019970709962A patent/KR100454554B1/ko not_active Expired - Fee Related
- 1996-07-01 CA CA2225675A patent/CA2225675C/en not_active Expired - Lifetime
- 1996-07-01 EP EP96924372A patent/EP0845943B1/de not_active Expired - Lifetime
1997
- 1997-12-29 NO NO19976094A patent/NO320715B1/no not_active IP Right Cessation
2000
- 2000-07-11 US US09/613,743 patent/US6682897B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2225675C (en)	2010-09-21
ZA965565B (en)	1997-02-26
HUP9901688A3 (en)	1999-12-28
EP0845943A4 (de)	2002-04-10
NO976094D0 (no)	1997-12-29
MX9800191A (es)	1998-05-31
IL122757A (en)	2001-07-24
EP0845943B1 (de)	2005-03-09
CZ295110B6 (cs)	2005-05-18
AR003446A1 (es)	1998-08-05
JPH11509196A (ja)	1999-08-17
CN1193889A (zh)	1998-09-23
CN1102598C (zh)	2003-03-05
DK0845943T3 (da)	2005-07-11
WO1997001959A1 (en)	1997-01-23
CZ411797A3 (cs)	1998-06-17
HUP9901688A2 (hu)	1999-09-28
US6682897B1 (en)	2004-01-27
DE69634438T2 (de)	2006-02-09
AU6484596A (en)	1997-02-05
UY24270A1 (es)	2000-12-29
NO976094L (no)	1998-02-02
IL114407A0 (en)	1995-10-31
DE69634438D1 (de)	2005-04-14
EP0845943A1 (de)	1998-06-10
KR100454554B1 (ko)	2005-04-06
ES2239770T3 (es)	2005-10-01
IL122757A0 (en)	1998-08-16
HRP960307A2 (en)	1998-04-30
JP3955627B2 (ja)	2007-08-08
CA2225675A1 (en)	1997-01-23
AU710882B2 (en)	1999-09-30
ATE290315T1 (de)	2005-03-15
KR19990028640A (ko)	1999-04-15

Legal Events

Date	Code	Title	Description
2016-07-11	MK1K	Patent expired

Publication	Publication Date	Title
JP3165148B2 (ja)	2001-05-14	インスリン依存性糖尿病の診断と治療
Elias et al.	1991	Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein.
AU710882B2 (en)	1999-09-30	Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
JP3942191B2 (ja)	2007-07-11	自己免疫疾患に関連する自己及び非自己抗原の同定
JP3554319B2 (ja)	2004-08-18	ペプチドｐ２７７類似体及びこれを含む糖尿病の治療又は診断のための薬剤組成物
MXPA06010364A (es)	2007-03-07	Identificacion de antigenos puros y no puros implicados en enfermedades autoinmunes.
JP2007000147A (ja)	2007-01-11	微生物ストレスタンパク質のペプチド断片、および該タンパク質もしくは断片の使用
US6110746A (en)	2000-08-29	Peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
US5578303A (en)	1996-11-26	Diagnosis and treatment of insulin dependent diabetes mellitus
Esaguy et al.	1993	Lactoferrin Triggers In Vitro Proliferation of T Cells of Lewis Rats Submitted to Mycobacteria‐Induced Adjuvant Arthritis
JP3955627B6 (ja)	2007-12-26	糖尿病の治療のためのヒト熱ショックタンパク質６０由来の新規ペプチド、組成物、方法およびキット
JP2007119482A (ja)	2007-05-17	糖尿病の治療のためのヒト熱ショックタンパク質６０由来の新規ペプチド、組成物、方法およびキット
CA3114446A1 (en)	2020-04-09	Recombinant polypeptides comprising modified mhc class ii dr.alpha.1 domains and methods of use
RU2159250C2 (ru)	2000-11-20	АНАЛОГИ ПЕПТИДА p277 И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ И ДИАГНОСТИКИ ДИАБЕТА
MXPA98000191A (en)	1998-10-23	Novedous peptides derived from human protein 60 produced by thermal shock, for the treatment of diabetes, compositions, methods and equi
US20040057961A1 (en)	2004-03-25	Human t cell response to mhc-binding motif clusters
IL94241A (en)	1996-03-31	Methods and kits for diagnosis of insulin dependent diabetes mellitus (iddm)